These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 36210299)
21. TheraP: a randomized phase 2 trial of Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341 [TBL] [Abstract][Full Text] [Related]
22. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038 [TBL] [Abstract][Full Text] [Related]
24. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090 [TBL] [Abstract][Full Text] [Related]
25. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060 [TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216 [TBL] [Abstract][Full Text] [Related]
27. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). Barata P; Cooney M; Tyler A; Wright J; Dreicer R; Garcia JA Invest New Drugs; 2018 Jun; 36(3):451-457. PubMed ID: 29476383 [TBL] [Abstract][Full Text] [Related]
28. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. Nakabayashi M; Werner L; Courtney KD; Buckle G; Oh WK; Bubley GJ; Hayes JH; Weckstein D; Elfiky A; Sims DM; Kantoff PW; Taplin ME BJU Int; 2012 Dec; 110(11):1729-35. PubMed ID: 22928480 [TBL] [Abstract][Full Text] [Related]
29. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ; Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048 [TBL] [Abstract][Full Text] [Related]
30. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555 [TBL] [Abstract][Full Text] [Related]
31. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN Clin Genitourin Cancer; 2015 Apr; 13(2):124-9. PubMed ID: 24993934 [TBL] [Abstract][Full Text] [Related]
32. PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study. Hammerer P; Al-Batran SE; Windemuth-Kieselbach C; Keller M; Hofheinz RD World J Urol; 2018 Mar; 36(3):375-381. PubMed ID: 29305637 [TBL] [Abstract][Full Text] [Related]
33. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624 [TBL] [Abstract][Full Text] [Related]